CYP2C19

Pharmacogenomics (PGx) allows the use of genetic fingerprints to predict individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Application of PGx in early-phase clinical trials can help in recognizing human genome variations that are meaningful to study design, selection of participants, allocation of resources and clinical research ethics. Prior research on the CYP2C19 gene has identified approximately 2,000 reference single nucleotide polymorphisms.

As such CYP2C19 metabolizes a number of drugs, including omeprazole, diazepam, antiplatelet drug clopidogrel, and antidepressants such as imipramine and citalopram. CYP2C19 metabolizing activity is classified into ultra-rapid, rapid, normal, intermediate or poor metabolizer, depending on the genotypic combination of an individual. GeneOmbio’s expertise in routine collection of biological samples, long-term storage of DNA, RNA and tissues, identifying research platforms as well as incorporation of PGx specific language into reporting can help CROs conduct better guided studies.